Short answer
Inhibikase Therapeutics, Inc. (IKT) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.
Inhibikase Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Corporate updates announced alongside quarterly results
- Detailed financial figures and updates contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 IMPROVE-PAH advancing: 28 countries approved and 79 of 180 planned sites activated
- Part A interim safety readout planned for first half of 2027, a near-term clinical catalyst
- Cash, equivalents and marketable securities $193.3M at September 30, 2026, with funding expected through Part B topline data assuming warrant exercise
- Quarterly net loss $20.5M versus $11.9M, while R&D expense rose to $15.0M from $7.6M as trial activity accelerates
- July financing raised $50M from 25,000,000 shares sold to RA Capital, followed by exchange of 18,030,000 shares for pre-funded warrants
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inhibikase Therapeutics, Inc. 8-K filings
Get the next IKT 8-K as it lands
Follow IKT for push alerts, or ask the research agent what this filing means.